Skip to content

Efficacy and Safety of VS002A With the Standard WHO-ORS in Non-cholera Acute Watery Diarrhea in Infants and Young Children

Clinical Trial to Compare the Efficacy and Safety of a Multiple Amino-acid Based ORS VS002A With the Standard WHO-ORS in the Management of Non-cholera Acute Watery Diarrhea in Infants and Young Children

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04677296
Enrollment
312
Registered
2020-12-21
Start date
2021-06-16
Completion date
2022-09-05
Last updated
2023-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diarrhea, Infantile

Brief summary

Randomized double blinded clinical trial comparing amino acid based oral rehydration solution/medical food and glucose-based oral rehydration solution is infectious diarrhea in pediatric population

Interventions

OTHERVS002A

Amino acid based ORS/Medical food

OTHERWHO-ORS

WHO Oral rehydration solution, which is glucose based

Sponsors

International Centre for Diarrhoeal Disease Research, Bangladesh
CollaboratorOTHER
Entrinsic Bioscience Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Intervention model description

Randomized double blinded

Eligibility

Sex/Gender
MALE
Age
6 Months to 36 Months
Healthy volunteers
No

Inclusion criteria

1. Age: 6 months - 36 months, 2. Duration of diarrhea ≤48 hours, 3. Some dehydration (judged clinically according to the Dhaka method), 4. Written informed consent by either parent/guardian.

Exclusion criteria

1. Severe malnutrition (Weight-for-length WLZ/WHZ/WAZ \<-3 or presence of nutritional edema) 2. Patients with diarrhea due to cholera. 3. Systemic illness (e.g. Pneumonia, tuberculosis, enteric fever, meningitis etc.) 4. Bloody diarrhea 5. Any congenital anomaly or disorder (e.g. diagnosed inborn error of metabolism, congenital cardiac disease, seizure disorders, hypothyroidism, Down's syndrome etc.) 6. Requirement of additional intravenous fluids after being provided with an IV for 4 hours on admission if severely dehydrated 7. Has documentation of taking antibiotic and/or antidiarrheal within the last 48 hours prior to hospitalization.

Design outcomes

Primary

MeasureTime frameDescription
Duration of diarrhea in hospital (hours)5 daysnumber of hours of diarrhea after randomization

Secondary

MeasureTime frameDescription
Total stool output5 daysTotal amount of stool output during the study
ORS intake in the 1st 24 hours of hospitalization1 dayAmount of intervention drink consumed in the first 24 hours after randomization
Total ORS intake5 daysAmount of intervention drink consumed throughout the duration of the study
Unscheduled IV (frequency/ORS group)5 daysFrequency of IV fluids between he 2 groups
Treatment failure (frequency/ORS group)5 daysFrequency of treatment failures between the two groups
Stool output1 dayStool output in the 1st 24 hours of hospitalization (g/kg body wt.), divided into two 12-hour periods
Change in body weight (between pre-randomization and post-treatment)5 daysBody weight at randomization and post treatment
Urine output in the 1st 24 hours of hospitalization (g/kg body wt.)1 dayAmount of urine in the first 24 hours after randomization
Total urine output during hospitalization5 daysTotal urine output (g/kg body wt.)
Documented infectious agent5 daysStool culture and recording of infectious agent causing the diarrhea
Output and frequency of vomiting5 daysAmount and frequency of vomiting between the two groups

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026